EpiCypher Joins PacBio Compatible Program To Enhance Single-Molecule Chromatin Sequencing With CUTANA Hia5 Enzyme

Author: Benzinga Newsdesk | September 03, 2025 09:06am

PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that EpiCypher, a recognized leader in epigenetics tools, has joined the PacBio Compatible program. The partnership brings EpiCypher's CUTANA® Hia5 enzyme to market for use with Fiber-seq assays on PacBio HiFi sequencing systems, giving researchers a new way to see chromatin biology at single-molecule resolution.

Fiber-seq (single-molecule chromatin fiber sequencing) is an advanced multi-omic whole genome sequencing (WGS) assay that simultaneously measures chromatin accessibility, DNA methylation, and DNA variation on individual DNA molecules. Unlike traditional short-read epigenetic assays like ATAC-seq, Fiber-seq using HiFi sequencing reveals the connections between multiple genetic and epigenetic features in a single assay, providing a powerful new approach to understand gene regulation and its impact on human health and disease.

As part of this collaboration, EpiCypher's Hia5 enzyme is now commercially available for use in Fiber-seq assays on PacBio's HiFi sequencing systems. By combining PacBio HiFi sequencing with EpiCypher's Hia5 enzyme, researchers can now:

• Explore how DNA is regulated at the level of individual molecules to better connect genetic variation directly to gene regulation.
• Interrogate complex regions of the genome that short-read approaches cannot resolve, including sequences tied to rare disease and other conditions.
• Consolidate multiple assays into one workflow, saving time and resources while delivering richer, more complete data.

Posted In: PACB